R

Retina-Vitreous Associates Medical Group | Beverly Hills, CA

Research site
(Unclaimed)
Location
9001 Wilshire Boulevard Suite 301, Beverly Hills, California, United States of America
Site insights

Top conditions

Macular Degeneration (40 trials)

Macular Edema (22 trials)

Edema (17 trials)

Geographic Atrophy (12 trials)

Atrophy (11 trials)

Top treatments

Ranibizumab
ranibizumab
UBX1325
NT-501
Faricimab
-Ranibizumab
Lampalizumab
bevacizumab
Denufosol
IONIS-FB-LRx

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

8 of 75
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema

Study BP43445 is a phase II, multicenter, randomized, double-masked, active comparator-controlled study to investigate the efficacy, safety, tolerabi...

Active, not recruiting
Diabetic Macular Edema
Drug: Ranibizumab
Drug: Vamikibart

This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with g...

Enrolling
Geographic Atrophy
Biological: OpRegen

The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Ed...

Enrolling
Edema
Diabetic Macular Edema
Drug: foselutoclax
Drug: Aflibercept

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in patients with neovas...

Enrolling
Neovascular Age-Related Macular Degeneration
Drug: PDS Implant with Ranibizumab 100 mg/mL

Evaluate the effect of IONIS-FB-LRx on the rate of change of the area of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)...

Active, not recruiting
Macular Degeneration
Geographic Atrophy
Drug: Placebo
Drug: IONIS-FB-LRx

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...

Enrolling
Wet Age-related Macular Degeneration
Wet AMD
Genetic: RGX-314
Biological: Ranibizumab (LUCENTIS®)

RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of diabetic retinopathy, a chronic and progressive...

Enrolling
Diabetic Retinopathy (DR)
Drug: Topical Steroid
Genetic: RGX-314 Dose 1

This study will evaluate the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranibizumab (PDS) in Participants with Diabetic...

Active, not recruiting
Diabetic Macular Edema
Drug: Intravitreal Ranibizumab 0.5 mg Injection
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab

Trial sponsors

Roche logo

Roche (10 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems